T-E Meds Presents TE-1146 NAMs Research in Collaboration with Anivance AI at World ADC
T-E Meds, a subsidiary of T-E Pharma, recently presented preclinical research progress on its ADC candidate TE-1146 at the World ADC conference in San Diego, USA. Dr. Hsing-Mao Chu, CEO of T-E Pharma, shared findings including selected safety assessment studies conducted in collaboration with Anivance AI using New Approach Methodologies (NAMs), human cell models, and
T-E Meds Presents TE-1146 NAMs Research in Collaboration with Anivance AI at World ADC Read More »
